Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI.
BACKGROUND:Irinotecan toxicity correlates with UGT1A1 activity. We explored whether phenotyping UGT1A1 using a probe approach works better than current genotyping methods. METHODS:Twenty-four Asian cancer patients received irinotecan as part of the FOLFIRI regimen. Subjects took raltegravir 400 mg o...
Main Authors: | Lawrence Soon-U Lee, Kok-Yong Seng, Ling-Zhi Wang, Wei-Peng Yong, Kim-Hor Hee, Thomas I Soh, Andrea Wong, Pei F Cheong, Richie Soong, Nur S Sapari, Ross Soo, Lu Fan, Soo-Chin Lee, Boon C Goh |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4726617?pdf=render |
Similar Items
-
Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting
by: Chien-Yu Lu, et al.
Published: (2015-12-01) -
UGT1A1 polymorphisms in cancer: impact on irinotecan treatment
by: Takano M, et al.
Published: (2017-02-01) -
Prevalence of the UGT1A1*6 (c.211G>A) polymorphism and irinotecan toxicity in Iranian populations of different ethnicities
by: Shakibi, Reyhaneh, et al.
Published: (2015) -
Cost-Effectiveness of UGT1A1*28 Genotyping in Preventing Severe Neutropenia Following FOLFIRI Therapy in Colorectal Cancer.
by: Solen Pichereau, et al.
Published: (2011-01-01) -
UGT1A6 polymorphisms modulated lung cancer risk in a Chinese population.
by: Ley-Fang Kua, et al.
Published: (2012-01-01)